TI
LXRX icon

Telemetry Investments’s Lexicon Pharmaceuticals LXRX Stock Holding History

Telemetry Investments’s Portfolio LXRX Stock Details LXRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q1 		– Sell
-25,500
Closed -$339K – 113
2015
Q4 		$339K Buy
+25,500
New +$314K 0.12% 95

Other funds holding LXRX

AG
Artal Group Luxembourg $931M AUM 41.63% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
UBS AM
UBS AM Chicago, Illinois $550B AUM 43.33% 1-Year Est. Return
UL
Ulys LLC New York $25.4M AUM 201.03% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
EAM
Eagle Asset Management St Petersburg, Florida $19.6B AUM 41.58% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Loomis, Sayles & Company
Loomis, Sayles & Company Boston, Massachusetts $79.8B AUM 16.05% 1-Year Est. Return

Telemetry Investments's LXRX Position: Q1 2016 in Review

Telemetry Investments sold out of Lexicon Pharmaceuticals (LXRX) in Q1 2016, closing a stake of 25,500 shares — an estimated $339K sold.

Telemetry Investments first reported a position in LXRX in Q4 2015 and held it in 1 quarter. The position peaked at $339K in Q4 2015. 132 funds tracked by Wall St. Rank hold LXRX as of Q1 2016.

  • Telemetry Investments reported no remaining Lexicon Pharmaceuticals position as of Q1 2016 after selling out during the quarter.
  • Telemetry Investments sold 25,500 Lexicon Pharmaceuticals shares in Q1 2016, an estimated $339K.
  • Telemetry Investments first reported a position in Lexicon Pharmaceuticals in Q4 2015 and held it in 1 quarter.
  • Telemetry Investments's Lexicon Pharmaceuticals position peaked at $339K in Q4 2015.
  • 132 funds tracked by Wall St. Rank held Lexicon Pharmaceuticals as of Q1 2016.

Based on Telemetry Investments's 13F filing for Q1 2016, filed 16 May 2016.